Singapore markets closed
  • Straits Times Index

    3,252.37
    -15.17 (-0.46%)
     
  • S&P 500

    3,998.84
    -72.86 (-1.79%)
     
  • Dow

    33,947.10
    -482.78 (-1.40%)
     
  • Nasdaq

    11,239.94
    -221.56 (-1.93%)
     
  • BTC-USD

    16,997.06
    -319.40 (-1.84%)
     
  • CMC Crypto 200

    401.07
    -10.14 (-2.47%)
     
  • FTSE 100

    7,560.01
    -7.53 (-0.10%)
     
  • Gold

    1,783.70
    +2.40 (+0.13%)
     
  • Crude Oil

    77.05
    +0.12 (+0.16%)
     
  • 10-Yr Bond

    3.5990
    0.0000 (0.00%)
     
  • Nikkei

    27,885.87
    +65.47 (+0.24%)
     
  • Hang Seng

    19,441.18
    -77.11 (-0.40%)
     
  • FTSE Bursa Malaysia

    1,471.55
    -0.01 (-0.00%)
     
  • Jakarta Composite Index

    6,892.57
    -94.76 (-1.36%)
     
  • PSE Index

    6,674.38
    +232.25 (+3.61%)
     

Got $2,000? Buy These 2 Bear Market-Beating Growth Stocks

Got $2,000? Buy These 2 Bear Market-Beating Growth Stocks

With the market down by more than 21% in 2022, we're officially in a bear market, and many investors are scrambling to protect themselves. AbbVie's (NYSE: ABBV) stock is up 9.9% this year, and with a bunch of recently reported clinical trial results and green lights from regulators, it isn't too surprising why. Most recently, on Sept. 10, it announced that a pair of its phase 3 trials of Skyrizi, a psoriatic arthritis drug that's already on the market, showed that the drug was performing favorably in long-term followup studies.